APP and Alzheimer disease: To confirm the therapeutic effects of peripheral administration of FGF21 in a symptomatic transgenic animal model of AD, we used six-month-old male APP/PS1 transgenic mice (subcutaneously injected with FGF21 at 5 mg/kg/d for one month) (Figure 1A).